Antipsychotics at doses greater than 75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study published in the Journal of Clinical Psychopharmacology. The researchers examined the association between antipsychotic doses and the risk for TD in clinical practice in a population of patients aged 15 years or older with a diagnosis of schizophrenia, depression, or bipolar disorder. Patients newly diagnosed with TD were matched with a control group in a 1:10 ratio. The analysis population included 58,452 patients; 80 were identified as TD cases. The researchers found that doses greater than 75 mg/day at the last prescription and as the maximum dose before the date of TD diagnosis were associated with a significantly increased risk for TD. The odds ratios were 3.40 and 3.50 when comparing doses greater than or equal to 300 mg/day with doses ranging from 75 to 300 mg/day at the last prescription and as the maximum dose before the first diagnosis of TD, respectively.
The post Antipsychotic Dose Linked to Tardive Dyskinesia Risk first appeared on Physician's Weekly.